DE3729209A1 - Verwendung von bezafibrat zur behandlung von diabetes - Google Patents

Verwendung von bezafibrat zur behandlung von diabetes

Info

Publication number
DE3729209A1
DE3729209A1 DE19873729209 DE3729209A DE3729209A1 DE 3729209 A1 DE3729209 A1 DE 3729209A1 DE 19873729209 DE19873729209 DE 19873729209 DE 3729209 A DE3729209 A DE 3729209A DE 3729209 A1 DE3729209 A1 DE 3729209A1
Authority
DE
Germany
Prior art keywords
bezafibrate
treatment
insulin
diabetes mellitus
normolipidemic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE19873729209
Other languages
German (de)
English (en)
Other versions
DE3729209C2 (enExample
Inventor
Walter Dipl Chem Dr Rer N Beck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim GmbH filed Critical Boehringer Mannheim GmbH
Priority to DE19873729209 priority Critical patent/DE3729209A1/de
Priority to IE252988A priority patent/IE62189B1/en
Priority to DK472688A priority patent/DK472688A/da
Priority to AT88113831T priority patent/ATE95694T1/de
Priority to DE88113831T priority patent/DE3884895D1/de
Priority to HU884456A priority patent/HU200687B/hu
Priority to IL87566A priority patent/IL87566A0/xx
Priority to ES88113831T priority patent/ES2059457T3/es
Priority to EP88113831A priority patent/EP0305890B1/de
Priority to AU21586/88A priority patent/AU610228B2/en
Priority to PH37464A priority patent/PH24568A/en
Priority to ZA886459A priority patent/ZA886459B/xx
Priority to PT88383A priority patent/PT88383B/pt
Priority to CA000576196A priority patent/CA1323575C/en
Priority to JP63216469A priority patent/JP2647918B2/ja
Priority to KR1019880011350A priority patent/KR890004690A/ko
Publication of DE3729209A1 publication Critical patent/DE3729209A1/de
Application granted granted Critical
Publication of DE3729209C2 publication Critical patent/DE3729209C2/de
Priority to US07/993,525 priority patent/US5304575A/en
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE19873729209 1987-09-01 1987-09-01 Verwendung von bezafibrat zur behandlung von diabetes Granted DE3729209A1 (de)

Priority Applications (17)

Application Number Priority Date Filing Date Title
DE19873729209 DE3729209A1 (de) 1987-09-01 1987-09-01 Verwendung von bezafibrat zur behandlung von diabetes
IE252988A IE62189B1 (en) 1987-09-01 1988-08-18 Use of bezafibrate for treating diabetes
DK472688A DK472688A (da) 1987-09-01 1988-08-24 Anvendelse af bezafibrat til behandling af diabetes
EP88113831A EP0305890B1 (de) 1987-09-01 1988-08-25 Verwendung von Bezafibrat zur Behandlung von Diabetes
DE88113831T DE3884895D1 (de) 1987-09-01 1988-08-25 Verwendung von Bezafibrat zur Behandlung von Diabetes.
HU884456A HU200687B (en) 1987-09-01 1988-08-25 Process for producing pharmaceutical composition comprising bezafibrate as active ingredient and suitable for treating normolipidaemic diabetes
IL87566A IL87566A0 (en) 1987-09-01 1988-08-25 Medical composition for the treatment of diabetes comprising a benzamide derivative
ES88113831T ES2059457T3 (es) 1987-09-01 1988-08-25 Utilizacion de bezafibrato para el tratamiento de la diabetes.
AT88113831T ATE95694T1 (de) 1987-09-01 1988-08-25 Verwendung von bezafibrat zur behandlung von diabetes.
PH37464A PH24568A (en) 1987-09-01 1988-08-26 Use of bezafibrate for treating diabetes
AU21586/88A AU610228B2 (en) 1987-09-01 1988-08-26 Use of bezafibrate for treating diabetes
ZA886459A ZA886459B (en) 1987-09-01 1988-08-31 Use of bezafibrate for treating diabetes
PT88383A PT88383B (pt) 1987-09-01 1988-08-31 Processo para a preparacao de composicoes farmaceuticas contendo acido 2-<4-{2-(4-clorobenzamido)-etil}-fenoxi>-2-metil-propoionico apropriadas para o tratamento de diabetes
CA000576196A CA1323575C (en) 1987-09-01 1988-08-31 Use of bezafibrate for treating diabetes
JP63216469A JP2647918B2 (ja) 1987-09-01 1988-09-01 正常脂血症性真性糖尿病▲ｉｉ▼型の予防剤
KR1019880011350A KR890004690A (ko) 1987-09-01 1988-09-01 당뇨병의 치료를 위한 베자피브레이드의 용도
US07/993,525 US5304575A (en) 1987-09-01 1992-12-17 Use of bezafibrate for treating diabetes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19873729209 DE3729209A1 (de) 1987-09-01 1987-09-01 Verwendung von bezafibrat zur behandlung von diabetes

Publications (2)

Publication Number Publication Date
DE3729209A1 true DE3729209A1 (de) 1989-03-09
DE3729209C2 DE3729209C2 (enExample) 1989-08-03

Family

ID=6334986

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19873729209 Granted DE3729209A1 (de) 1987-09-01 1987-09-01 Verwendung von bezafibrat zur behandlung von diabetes
DE88113831T Expired - Fee Related DE3884895D1 (de) 1987-09-01 1988-08-25 Verwendung von Bezafibrat zur Behandlung von Diabetes.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE88113831T Expired - Fee Related DE3884895D1 (de) 1987-09-01 1988-08-25 Verwendung von Bezafibrat zur Behandlung von Diabetes.

Country Status (16)

Country Link
US (1) US5304575A (enExample)
EP (1) EP0305890B1 (enExample)
JP (1) JP2647918B2 (enExample)
KR (1) KR890004690A (enExample)
AT (1) ATE95694T1 (enExample)
AU (1) AU610228B2 (enExample)
CA (1) CA1323575C (enExample)
DE (2) DE3729209A1 (enExample)
DK (1) DK472688A (enExample)
ES (1) ES2059457T3 (enExample)
HU (1) HU200687B (enExample)
IE (1) IE62189B1 (enExample)
IL (1) IL87566A0 (enExample)
PH (1) PH24568A (enExample)
PT (1) PT88383B (enExample)
ZA (1) ZA886459B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655699B1 (en) 1992-04-22 2010-02-02 Eisai Inc. Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US7115728B1 (en) 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
WO1998005331A2 (en) * 1996-08-02 1998-02-12 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
WO1999005161A1 (en) * 1997-07-25 1999-02-04 Ligand Pharmaceuticals Incorporated HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARη) GENE REGULATORY SEQUENCES AND USES THEREFOR
FR2774591B1 (fr) 1998-02-12 2000-05-05 Lipha Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
JP4879433B2 (ja) * 2000-01-13 2012-02-22 エミスフェアー・テクノロジーズ・インク 活性剤を送達するための化合物および組成物
CN1332711C (zh) 2002-02-20 2007-08-22 埃米球科技有限公司 施用glp－1分子的方法
US7264813B2 (en) * 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
US20060286129A1 (en) * 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
US20070197602A1 (en) * 2004-02-09 2007-08-23 Hashime Kanazawa Combined pharmaceutical composition
FR2898894B1 (fr) * 2006-03-24 2008-06-06 Genfit Sa Composes derives de n-(phenethyl)benzamide substitues, preparation et utilisations
US10098860B2 (en) 2016-07-20 2018-10-16 Cipla Limited Bezafibrate for the treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2149070A1 (de) * 1971-10-01 1973-04-05 Boehringer Mannheim Gmbh Phenoxyalkylcarbonsaeurederivate und verfahren zur herstellung derselben

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56145261A (en) * 1980-04-10 1981-11-11 Kaken Pharmaceut Co Ltd Novel oxyacetic acid derivative, its preparation, and lowering agent of lipid in blood comprising it as active ingredient

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2149070A1 (de) * 1971-10-01 1973-04-05 Boehringer Mannheim Gmbh Phenoxyalkylcarbonsaeurederivate und verfahren zur herstellung derselben

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BRUNEDER et al. DMW, 106, 1981, S. 1653-1656 *

Also Published As

Publication number Publication date
AU610228B2 (en) 1991-05-16
AU2158688A (en) 1989-05-25
JP2647918B2 (ja) 1997-08-27
IE62189B1 (en) 1994-12-28
HU200687B (en) 1990-08-28
PH24568A (en) 1990-08-03
EP0305890A2 (de) 1989-03-08
IL87566A0 (en) 1989-01-31
KR890004690A (ko) 1989-05-09
US5304575A (en) 1994-04-19
DK472688D0 (da) 1988-08-24
DE3884895D1 (de) 1993-11-18
JPS6471813A (en) 1989-03-16
CA1323575C (en) 1993-10-26
PT88383A (pt) 1989-07-31
PT88383B (pt) 1992-10-30
HUT47427A (en) 1989-03-28
ES2059457T3 (es) 1994-11-16
EP0305890B1 (de) 1993-10-13
ZA886459B (en) 1989-05-30
EP0305890A3 (en) 1990-08-22
DK472688A (da) 1989-03-02
DE3729209C2 (enExample) 1989-08-03
ATE95694T1 (de) 1993-10-15
IE882529L (en) 1989-03-01

Similar Documents

Publication Publication Date Title
DE69800806T2 (de) Neue dosierung für diabetes type 2
DE69109376T2 (de) Hemmung von Muskelschwund und Proteinabbau von Muskeln bei Säugetieren durch Tetrazyklines.
DE3729209C2 (enExample)
DE69529249T2 (de) Puderpräparat zur Heilung verletzter Haut
DE69927125T2 (de) Zusammensetzung gegen Erhöhung oder zur Herabsetzung des Blutzuckerspiegels
DE3247062C2 (enExample)
DE69829042T2 (de) Nicotinsäurezusammensetzungen enthaltender Starterkit
DE2241740A1 (de) Pharmazeutische packungen
DE3883606T2 (de) Verwendung von Fluoxetin zur Behandlung des Diabetes.
DE4214953C2 (de) Arzneimittel zur Erhöhung des Testosteronspiegels
DE3137125A1 (de) Verwendung von pyridoxin-(alpha)-ketoglutarat fuer die prophylaxe der hyperlactacidaemie
DE3880587T2 (de) Verwendung von bestimmten calcium-citrate-malaten zur herstellung einer pharmazeutischen zubereitung fuer die behandlung von osteoporose.
DD273977A5 (de) Verfahren zur herstellung eines stomatologischen praeparates
EP0398165B1 (de) Kombinationspräparate enthaltend Rifampicin und Thioacetazon sowie gegebenenfalls Isonicotinsäurehydrazid oder Ethambutol als aktive Wirkstoffe
DE2335216A1 (de) Arzneimittel zur foerderung der proteinsynthese und zur unterdrueckung der harnstoffbildung
DE2529149A1 (de) Topisch anwendbare mittel gegen akne vulgaris
EP0212310B1 (de) Verwendung von Probucol zur Herstellung eines Arzneimittels für die Behandlung von Herzarrhythmie
EP0075823B1 (de) Verwendung von basisch substituierten Phenylacetonitrilen bei der vorbeugenden Bekämpfung von Krankheiten
EP0407634B1 (de) Schmerzstillendes und entzündungshemmendes Arzneimittel
DE2161588C3 (de) Mittel zur Behandlung von Hyperlipoproteinämien
DE69019956T2 (de) Pharmazeutische zusammensetzungen zur behandlung von hauterkrankungen, insbesondere pyogener und atopischer dermatitis und verfahren zu deren herstellung.
EP0820771A2 (de) Arzneimittel zur Behandlung von Neuropathien, das ein lipidlösliches Thiamin und eine Magnesiumverbindung enthält
DE2117762A1 (de) Behandlung von Alopecia und pharmazeutische Präparation für die Durchführung der Behandlung
DE2630326C2 (de) Präparat zur Behandlung der Osteoporose und seine Herstellung
Groh et al. ORALE DAUERTHERAPIE MIT CLONAZEPAM (Ro 5‐4023) BEI EPILEPSIEN DES KINDES‐UND JUGENDALTERS

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee